{"id":"nb-001-0-3","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NanoBio Corporation's NB-001 utilizes nanoparticle technology to create a stable emulsion that improves drug delivery across biological barriers. The 0.3% formulation suggests a topical or mucosal application intended to maximize local therapeutic effect while minimizing systemic exposure. This approach is characteristic of NanoBio's platform for enhancing penetration of active pharmaceutical ingredients.","oneSentence":"NB-001 is a nanoemulsion formulation designed to deliver antimicrobial or antiviral agents topically with enhanced penetration and bioavailability.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:48.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01695187","phase":"PHASE3","title":"NB-001 Treatment of Recurrent Herpes Labialis","status":"UNKNOWN","sponsor":"NanoBio Corporation","startDate":"2012-10","conditions":"Herpes Labialis","enrollment":362},{"nctId":"NCT01321359","phase":"PHASE3","title":"A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis","status":"COMPLETED","sponsor":"NanoBio Corporation","startDate":"2011-04","conditions":"Recurrent Herpes Simplex Labialis","enrollment":907},{"nctId":"NCT01324466","phase":"PHASE3","title":"A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)","status":"COMPLETED","sponsor":"NanoBio Corporation","startDate":"2011-04","conditions":"Recurrent Herpes Labialis","enrollment":847},{"nctId":"NCT00453401","phase":"PHASE2","title":"Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis","status":"COMPLETED","sponsor":"NanoBio Corporation","startDate":"2007-02","conditions":"Herpes Labialis","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NB-001 (0.3%)","genericName":"NB-001 (0.3%)","companyName":"NanoBio Corporation","companyId":"nanobio-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}